MDGL FY 2009 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

FY 2009 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$144M+5416.1% YoY

Gross Profit

$00.0% margin

Operating Income

$81M55.8% margin

Net Income

$79M54.8% margin

EPS (Diluted)

$81.20

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$49M

Total Liabilities

$24M

Stockholders' Equity

$25M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$144M	$3M	+5416.1%
Gross Profit	$0	$0	—
Operating Income	$81M	-$94M	+185.9%
Net Income	$79M	-$93M	+185.4%